CN104189911A - 眼科组合物中的防腐剂替代物聚维酮碘 - Google Patents
眼科组合物中的防腐剂替代物聚维酮碘 Download PDFInfo
- Publication number
- CN104189911A CN104189911A CN201410353170.8A CN201410353170A CN104189911A CN 104189911 A CN104189911 A CN 104189911A CN 201410353170 A CN201410353170 A CN 201410353170A CN 104189911 A CN104189911 A CN 104189911A
- Authority
- CN
- China
- Prior art keywords
- pvp
- preparation
- povidone iodine
- ophthalmic
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 title claims abstract description 69
- 239000000203 mixture Substances 0.000 title abstract description 45
- 229920000153 Povidone-iodine Polymers 0.000 title description 28
- 229960001621 povidone-iodine Drugs 0.000 title description 28
- 239000003755 preservative agent Substances 0.000 title description 8
- 230000002335 preservative effect Effects 0.000 title description 7
- FAAHNQAYWKTLFD-UHFFFAOYSA-N 1-butan-2-ylpyrrolidin-2-one Chemical compound CCC(C)N1CCCC1=O FAAHNQAYWKTLFD-UHFFFAOYSA-N 0.000 claims abstract description 3
- -1 hydroxypropyl Chemical group 0.000 claims description 11
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 7
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 7
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 7
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 229960003702 moxifloxacin Drugs 0.000 claims description 3
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 abstract description 12
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 10
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 230000003266 anti-allergic effect Effects 0.000 abstract description 4
- 230000003637 steroidlike Effects 0.000 abstract 2
- 230000001384 anti-glaucoma Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 24
- 230000002421 anti-septic effect Effects 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000003814 drug Substances 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 230000000845 anti-microbial effect Effects 0.000 description 11
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 9
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- 239000006184 cosolvent Substances 0.000 description 7
- 229960003957 dexamethasone Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 7
- 229920001664 tyloxapol Polymers 0.000 description 7
- 229960004224 tyloxapol Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000000607 artificial tear Substances 0.000 description 6
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 239000004094 surface-active agent Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229940068984 polyvinyl alcohol Drugs 0.000 description 5
- 229960002800 prednisolone acetate Drugs 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 235000011152 sodium sulphate Nutrition 0.000 description 5
- 239000001117 sulphuric acid Substances 0.000 description 5
- 235000011149 sulphuric acid Nutrition 0.000 description 5
- 229960000707 tobramycin Drugs 0.000 description 5
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 5
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 3
- OTIWYSKRSMXGNK-VHJGTCNUSA-K Polidronium chloride Chemical compound [Cl-].[Cl-].[Cl-].OCC[N+](CCO)(CCO)C/C=C/C[N+](C)(C)C\C=C\C[N+](CCO)(CCO)CCO OTIWYSKRSMXGNK-VHJGTCNUSA-K 0.000 description 3
- 108010093965 Polymyxin B Proteins 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000000227 bioadhesive Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229960004926 chlorobutanol Drugs 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 229960003630 ketotifen fumarate Drugs 0.000 description 3
- YNQQEYBLVYAWNX-WLHGVMLRSA-N ketotifen fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 YNQQEYBLVYAWNX-WLHGVMLRSA-N 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- IDIIJJHBXUESQI-DFIJPDEKSA-N moxifloxacin hydrochloride Chemical compound Cl.COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 IDIIJJHBXUESQI-DFIJPDEKSA-N 0.000 description 3
- 229960005112 moxifloxacin hydrochloride Drugs 0.000 description 3
- 229940100654 ophthalmic suspension Drugs 0.000 description 3
- 229960000420 polidronium chloride Drugs 0.000 description 3
- 229920000024 polymyxin B Polymers 0.000 description 3
- 229960005266 polymyxin b Drugs 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000004334 sorbic acid Substances 0.000 description 3
- 235000010199 sorbic acid Nutrition 0.000 description 3
- 229940075582 sorbic acid Drugs 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229940033663 thimerosal Drugs 0.000 description 3
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- JJOFNSLZHKIJEV-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid Chemical compound OCC(N)(CO)CO.OCC(N)(CO)CO.OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl JJOFNSLZHKIJEV-UHFFFAOYSA-N 0.000 description 2
- 108010001478 Bacitracin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- GZENKSODFLBBHQ-ILSZZQPISA-N Medrysone Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@H](C(C)=O)CC[C@H]21 GZENKSODFLBBHQ-ILSZZQPISA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960003071 bacitracin Drugs 0.000 description 2
- 229930184125 bacitracin Natural products 0.000 description 2
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 2
- 229960003655 bromfenac Drugs 0.000 description 2
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 229960000590 celecoxib Drugs 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 210000000795 conjunctiva Anatomy 0.000 description 2
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 description 2
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 2
- 229960002344 dexamethasone sodium phosphate Drugs 0.000 description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- 229960004875 difluprednate Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229960001629 fluorometholone acetate Drugs 0.000 description 2
- YRFXGQHBPBMFHW-SBTZIJSASA-N fluorometholone acetate Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 YRFXGQHBPBMFHW-SBTZIJSASA-N 0.000 description 2
- 229960003898 flurbiprofen sodium Drugs 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 229960001067 hydrocortisone acetate Drugs 0.000 description 2
- UODNOPRRAQRYBM-UHFFFAOYSA-N hydroxy carbonofluoridate Chemical compound OOC(F)=O UODNOPRRAQRYBM-UHFFFAOYSA-N 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229960003943 hypromellose Drugs 0.000 description 2
- 229940059904 light mineral oil Drugs 0.000 description 2
- 229960000558 lodoxamide tromethamine Drugs 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960001011 medrysone Drugs 0.000 description 2
- 229960002009 naproxen Drugs 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229960001002 nepafenac Drugs 0.000 description 2
- QEFAQIPZVLVERP-UHFFFAOYSA-N nepafenac Chemical compound NC(=O)CC1=CC=CC(C(=O)C=2C=CC=CC=2)=C1N QEFAQIPZVLVERP-UHFFFAOYSA-N 0.000 description 2
- 239000002997 ophthalmic solution Substances 0.000 description 2
- 229940054534 ophthalmic solution Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 2
- 229960001487 rimexolone Drugs 0.000 description 2
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 2
- 229960000371 rofecoxib Drugs 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- GNMBMOULKUXEQF-UHFFFAOYSA-M sodium;2-(3-fluoro-4-phenylphenyl)propanoate;dihydrate Chemical compound O.O.[Na+].FC1=CC(C(C([O-])=O)C)=CC=C1C1=CC=CC=C1 GNMBMOULKUXEQF-UHFFFAOYSA-M 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 229960004492 suprofen Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- ZXBDZLHAHGPXIG-VTXLJDRKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ZXBDZLHAHGPXIG-VTXLJDRKSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 description 1
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- XYLJNLCSTIOKRM-UHFFFAOYSA-N Alphagan Chemical compound C1=CC2=NC=CN=C2C(Br)=C1NC1=NCCN1 XYLJNLCSTIOKRM-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 108010026389 Gramicidin Proteins 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 1
- 241001136616 Methone Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- HVRLZEKDTUEKQH-NOILCQHBSA-N Olopatadine hydrochloride Chemical compound Cl.C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 HVRLZEKDTUEKQH-NOILCQHBSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000190932 Rhodopseudomonas Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003260 anti-sepsis Effects 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- YEJAJYAHJQIWNU-UHFFFAOYSA-N azelastine hydrochloride Chemical compound Cl.C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 YEJAJYAHJQIWNU-UHFFFAOYSA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 description 1
- 229960004347 betaxolol hydrochloride Drugs 0.000 description 1
- 229960002470 bimatoprost Drugs 0.000 description 1
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical compound CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 description 1
- 229960003679 brimonidine Drugs 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960000265 cromoglicic acid Drugs 0.000 description 1
- 229940109248 cromoglycate Drugs 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000325 emedastine Drugs 0.000 description 1
- KBUZBQVCBVDWKX-UHFFFAOYSA-N emedastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1N1CCCN(C)CC1 KBUZBQVCBVDWKX-UHFFFAOYSA-N 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960003449 epinastine Drugs 0.000 description 1
- WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 description 1
- 229950009769 etabonate Drugs 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 150000002241 furanones Chemical class 0.000 description 1
- 229960003923 gatifloxacin Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 231100000734 genotoxic potential Toxicity 0.000 description 1
- 229960004905 gramicidin Drugs 0.000 description 1
- ZWCXYZRRTRDGQE-SORVKSEFSA-N gramicidina Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC=3C4=CC=CC=C4NC=3)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC=O)C(C)C)CC(C)C)C(=O)NCCO)=CNC2=C1 ZWCXYZRRTRDGQE-SORVKSEFSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229940064238 ilotycin Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000000937 inactivator Effects 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229960001160 latanoprost Drugs 0.000 description 1
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 description 1
- 229960000831 levobunolol Drugs 0.000 description 1
- IXHBTMCLRNMKHZ-LBPRGKRZSA-N levobunolol Chemical compound O=C1CCCC2=C1C=CC=C2OC[C@@H](O)CNC(C)(C)C IXHBTMCLRNMKHZ-LBPRGKRZSA-N 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229960004305 lodoxamide Drugs 0.000 description 1
- RVGLGHVJXCETIO-UHFFFAOYSA-N lodoxamide Chemical compound OC(=O)C(=O)NC1=CC(C#N)=CC(NC(=O)C(O)=O)=C1Cl RVGLGHVJXCETIO-UHFFFAOYSA-N 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960003085 meticillin Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229960004398 nedocromil Drugs 0.000 description 1
- RQTOOFIXOKYGAN-UHFFFAOYSA-N nedocromil Chemical compound CCN1C(C(O)=O)=CC(=O)C2=C1C(CCC)=C1OC(C(O)=O)=CC(=O)C1=C2 RQTOOFIXOKYGAN-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960004114 olopatadine Drugs 0.000 description 1
- JBIMVDZLSHOPLA-LSCVHKIXSA-N olopatadine Chemical compound C1OC2=CC=C(CC(O)=O)C=C2C(=C/CCN(C)C)\C2=CC=CC=C21 JBIMVDZLSHOPLA-LSCVHKIXSA-N 0.000 description 1
- 229960003139 olopatadine hydrochloride Drugs 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229960004439 pemirolast Drugs 0.000 description 1
- HIANJWSAHKJQTH-UHFFFAOYSA-N pemirolast Chemical compound CC1=CC=CN(C2=O)C1=NC=C2C=1N=NNN=1 HIANJWSAHKJQTH-UHFFFAOYSA-N 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229940096013 polymyxin b / trimethoprim Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 229960000454 timolol hemihydrate Drugs 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- 229940110746 tobramycin ophthalmic solution Drugs 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960002368 travoprost Drugs 0.000 description 1
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L12/00—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor
- A61L12/08—Methods or apparatus for disinfecting or sterilising contact lenses; Accessories therefor using chemical substances
- A61L12/10—Halogens or compounds thereof
- A61L12/105—Iodine, iodides or iodophores
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Plant Pathology (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明包括一种防腐的眼科制剂,该制剂包括浓度足以使所述眼科制剂防腐的聚维酮碘(PVP-I),和至少有一种选自下的组分:甾体抗炎化合物,非甾体抗炎化合物,抗菌化合物,抗过敏的化合物和抗青光眼化合物。本发明还包括在眼科药剂中添加PVP-I以使该药剂防腐,其中加入的PVP-I的浓度足以使该药剂防腐。
Description
本申请是申请号为200980122263.7(国际申请号为PCT/US2009/003521)、申请日为2009年6月10日、发明名称为“一种眼科组合物中新的防腐剂替代物聚维酮碘”的中国专利申请的分案申请。
本申请要求于2008年6月12日递交的61/129,222号美国临时申请和2008年12月15日递交的61/201,854号美国临时申请的优先权,上述两篇申请被全文引入本申请作为参考。
技术领域
本发明涉及防腐的眼科制剂,尤其涉及包含聚维酮碘作为防腐剂的眼科制剂。
背景技术
目前,防腐剂是眼科制剂的组成部分。通常添加适当的抗菌性防腐剂以防止多剂量包装污染。这类物质包括苯扎氯铵,硫柳汞,三氯叔丁醇,尼泊金甲酯,尼泊金丙酯,苯乙基醇,EDTA,山梨酸,泊利氯铵(Onamer M),以及本领域技术人员公知的其他抗菌性防腐剂,或它们的组合。苯扎氯铵(也称为BAK或BAC)是眼科制剂中最常用的防腐剂。通常情况下,这种防腐剂的用量以重量计为0.001%至1.0%。然而,最近有证据警示BAK对角膜和结膜的潜在毒性,这可能导致严重的医疗问题例如药物性眼病(ocular medicamentosa),降低的青光眼手术成功率,减少的眼部用药顺从性。
发明内容
本发明包括一种防腐的眼科制剂,该眼科制剂包含浓度足以使该眼科制剂防腐的聚维酮碘(PVP-I),和至少一种选自以下组分:甾体类抗炎化合物,非甾体类抗炎药化合物,抗菌化合物,抗过敏化合物,和抗青光眼化合物。
在一个实施方案中,PVP-I以选自以下组的浓度而存在:0.01%至10%,0.1%至2.5%,0.2至1.5%,0.3%至1.0%。在另一个实施方案中,PVP-I以0.5%的浓度而存在。
在一个实施方案中,PVP-I的浓度是基于整个制剂的重量/重量为基础测量得到的。在另一个实施方案中,PVP-I的浓度是基于整个制剂的重量/体积为基础测量得到的。
在一个实施方案中,制剂包含选自以下组的抗炎化合物:富马酸酮替芬,双氯芬酸钠,奈帕芬胺,溴芬酸,氟比洛芬钠,舒洛芬,塞来考昔,萘普生,罗非考昔,和它们任意的组合。
在一个实施方案中,制剂进一步包含选自以下组的抗炎化合物:地塞米松,地塞米松醇,地塞米松磷酸钠,醋酸氟米龙,氟米龙醇,依碳酸洛替泼诺(lotoprendol etabonate),甲羟松,醋酸泼尼松龙,泼尼松龙磷酸钠,二氟泼尼酯,利美索龙,氢化可的松,醋酸氢化可的松,洛度沙胺氨丁三醇,和它们任意的组合。
在一个实施方案中,制剂进一步包含选自以下组的抗菌性防腐剂:苯扎氯铵,硫柳汞,三氯叔丁醇,尼泊金甲酯,尼泊金丙酯,苯乙醇,EDTA,山梨酸,泊利氯铵(Onamer M)和它们的任意组合。
在一个实施方案中,制剂进一步包含增粘剂。在一个实施方案中,增粘剂选自聚乙烯醇,聚乙烯吡咯烷酮,甲基纤维素,羟丙基甲基纤维素,羟乙基纤维素,羧甲基纤维素,羟丙基纤维素,和它们任意的组合。
在一个实施方案中,制剂进一步包含至少一种基于人工泪液的润滑剂。
本发明还包括一种使眼科药剂防腐的方法,该方法包括在眼科药剂中添加足以使该药剂防腐的量的PVP-I。在一个实施方案中,该方法中添加的PVP-I浓度选自以下组:0.01%至10%,0.1%至2.5%,0.2至1.5%,0.3%至1.0%。在一个实施方案中,PVP-I以0.5%的浓度而存在。
具体实施方式
本申请中所使用的术语“约”是指参考值的上下10%范围内,包括该数值。
此处所述的范围包括参考值的两个端点值间的所有数值,包括两个端点值。
本发明中,发现聚维酮碘可以作为多种药物组合物的防腐剂,本发明的一方面,聚维酮碘作为眼科制剂的防腐剂。因此,在一个实施方案中,本发明提供防腐的眼科药剂,其包含聚维酮碘组合物。
在一个实施方案中,聚维酮碘至少具有对多种药物组合物的防腐作用。在一个实施方式中,聚维酮碘作为眼科药剂的防腐剂。在眼用组合物中作为防腐剂的聚维酮碘的浓度范围可以为0.01%-10%(重量/重量或重量/体积),以及所有该范围内的浓度值。在一个实施方案中,聚维酮碘浓度为0.1%至2.5%,在另一个实施方案中,为0.2%至1.5%,在另外的一个实施方案中,为0.3%至1.0%。在一个实施方案中,聚维酮碘浓度约为0.5%。
本发明的一方面,聚维酮碘为眼科制剂提供了抗菌性能。另一个方面,眼科制剂中的聚维酮碘提供了一种或多种非抗菌防腐性能(如作为抗氧化剂)。
在一个实施方案中,如此处所述,本发明还提供了聚维酮碘组合物,该组合物包含除聚维酮碘组分以外的一种或多种组分。
一方面,本发明提供一种广谱聚维酮碘眼科组合物,例如在由分枝杆菌,病毒,真菌和阿米巴引起的眼结膜或角膜感染时,使用含有防腐剂聚维酮碘的组合物。另一方面,本发明组合物伴随其它眼科措施可用于正从最近眼科手术后恢复病人的感染预防。
在不同的实施方案中,本发明的聚维酮碘眼科组合物包括但不限于以下内容:
1、包含防腐剂聚维酮碘的人工泪液制剂。人工泪液基质组分包括但不限于:眼科上可接受的润滑剂,丙二醇,甘油,聚乙二醇,葡聚糖,共混聚乙烯醇,聚乙烯醇,聚乙二醇,轻矿物油,羟丙基甲基纤维素,羟丙甲纤维素,聚羧乙烯,卡波姆940(聚丙烯酸),聚乙烯吡咯烷酮,白凡士林,大豆卵磷脂,羧甲基纤维素钠,以及所属技术领域人员公知的其他物质,或它们的任意组合。通常情况下,这种成分的用量以重量计为从0.1%到2%。在一个实施方案中,组分为丙二醇1.0%,甘油0.3%,共混聚乙烯醇2.7%,聚乙烯醇1%,聚乙二醇1%,轻矿物油,羟丙基甲基纤维素0.3%,大豆卵磷脂1.0%,羧甲基纤维素钠0.25%或0.5%。在另一个实施方案中,PVP-I和基于人工泪液的成分的总重量为组合物总量的0.1%至4.5%。
2、包含防腐剂聚维酮碘的抗炎和类固醇制剂。适合的抗炎药不限于以下实例:富马酸酮替芬,双氯芬酸钠,奈帕芬胺,溴芬酸,氟比洛芬钠,舒洛芬,塞来考昔,萘普生或罗非考昔。适合的类固醇类不限于以下实例:地塞米松醇,地塞米松磷酸钠,醋酸氟米龙,氟米龙醇,依碳酸洛替泼诺,甲羟松,醋酸泼尼松龙,泼尼松龙磷酸钠,二氟泼尼酯,利美索龙,氢化可的松,醋酸氢化可的松,洛度沙胺氨丁三醇。抗炎和类固醇成分的用量以重量计通常占组合物总重量的0.01%至2.0%。一方面,在防腐的眼科制剂中使用约0.1%地塞米松。
3、包含防腐剂聚维酮碘的用于治疗青光眼的无BAK眼科制剂。适合的青光眼药物不限于以下实例:β阻断剂(左布诺洛尔,噻吗洛尔半水化合物,盐酸倍他洛尔,马来酸噻吗洛尔,以及它们的相关盐);前列腺素类似物(例如比马前列素,曲伏前列素,拉坦前列素);α受体激动剂(溴莫尼定,爱必定,阿可乐宁);碳酸酐酶抑制剂(派立明,多佐胺)。这些组分的用量为本领域常规用量。
4、包含防腐剂聚维酮碘的抗菌/抗微生物眼科制剂。适合的抗生素/抗菌组分不限于以下实例:喹诺酮类(环丙沙星,左氧氟沙星,氧氟沙星,莫西沙星,加替沙星等);氨基糖苷类(妥布霉素,庆大霉素,新霉素等);多粘菌素B组合(多粘菌素B/甲氧苄啶,多链丝霉素多粘菌素B/杆菌肽新孢霉素多粘菌素B/新霉素/短杆菌肽等)和其他抗生素(阿奇霉素,红霉素(ilotycin),红霉素(erythromycin),杆菌肽等)。通常,这类抗生素和抗菌组分的用量以重量计为组合物总重量的0.001%至1.0%。
5、包含防腐剂聚维酮碘的抗过敏制剂。适合的抗过敏组分不限于以下实例:依匹斯汀,二富马酸依美斯汀,盐酸氮卓斯汀,盐酸奥洛他定,奥洛他定,富马酸酮替芬,吡嘧司特钾,奈多罗米,洛度沙胺,色甘酸和色甘酸盐。这些组分的用量为本领域常规用量。
6、含有防腐剂聚维酮碘的复合防腐眼科制剂。适合组分的实例不限于抗菌性防腐剂。在一个实施方案中,抗菌性防腐剂选自以下组:苯扎氯铵,硫柳汞,三氯叔丁醇,尼泊金甲酯,尼泊金丙酯,苯乙醇,EDTA,山梨酸,泊利氯铵和它们的组合。这些组分的用量为本领域常规用量。
此外,适合于本发明聚维酮碘组合物的辅料不限于以下实例:助溶剂/表面活性剂,粘度改变剂,和/或生物黏附剂。这些组分的用量为本领域常规用量。
一方面,本发明的组合物非必需地可包含一种助溶剂或表面活性剂。在一个实施方式中,助溶剂可以与表面活性剂相同或不同。在一个实施方案中,可通过在组合物中添加表面活性剂或适当的助溶剂来提高组合物中组分的溶解度。这种助溶剂/表面活性剂包括但不限于:聚山梨酯-20,聚山梨酯-60,聚山梨酯-80,聚氧乙烯/聚氧丙烯表面活性剂(如普朗尼克F-68和F-84和P-103),环糊精,泰洛沙泊(tyloxapol),聚乙二醇35蓖麻油(Cremophor EL),聚乙二醇40硬脂酸(Myrj52),以及所属领域人员公知的其他物质,或它们的任意组合。通常情况下,这些助溶剂的用量以重量计为0.01%至2%。
另一方面,本发明的组合物非必需地可包含一种任选的粘度增加剂或粘度降低剂。高于单一的水溶液的粘度可促进活性成分的眼部吸收,减少所配制药剂的差异性,减少悬浮液或微乳形式药剂中组分的物理分离和/或以其他方式改善眼科药剂。这种增粘剂包括但不限于:聚乙烯醇,聚乙烯吡咯烷酮,甲基纤维素,羟丙基甲基纤维素,羟乙基纤维素,羧甲基纤维素,羟丙基纤维素,以及所属领域人员公知的其他物质,和/或它们的任意组合。这些助溶剂的用量以重量计通常为0.01%至2%。
另一方面,组合物中可以包含生物黏附剂,以增加在生物基质上药物梯度的保留时间。生物黏附剂包括但不限于:聚乙烯吡咯烷酮(PVP),黄胞胶,豆角胶,金合欢胶,羟丙基甲基纤维素(HPMC),海藻酸钠,果胶,明胶,卡波姆,聚乙烯醇,结冷胶,黄蓍胶,阿拉伯胶和羧甲基纤维素钠,以及所属领域人员公知的其他试剂,或它们的任意组合。
此外,组合物可以与有效量的化学试剂结合以产生冰凉的感觉,当聚维酮碘溶液滴入眼睛时,可以缓解对眼部的刺激,增强眼部舒适度,产生提神的作用,并改善感觉。所述化学试剂包括多种化学物质及化合物种类,包括但不仅限于,清凉剂如薄荷,薄荷脑衍生物包括薄荷酮甘油缩醛(methone glycerinacetyl)和薄荷基酯类(menthyl esters),羧酰胺类,薄荷烷甘油缩酮类,烷基取代脲类,磺胺类,萜类类似物,呋喃酮类,和氧化磷;或樟脑和冰片。
所述含有聚维酮碘的组合物的制剂形式可以是溶液,悬浮液,乳剂,软膏,霜剂,凝胶,或控释/缓释制剂。例如,该组合物可以是隐形眼镜护理液,洗眼药水,滴眼液等形式。
任何用于局部给药——例如局部给药至眼睛——的本发明所公开的组合物,该混合物可以配置成pH值为3.5到6.5范围内的水溶液。应理解此处所述的范围意味着涵盖了范围的上限和下限。在一个实施方案中,pH值范围为4到5。该pH值范围可通过往溶液中滴加酸/碱的方法来实现。在另一个实施方案中,pH值范围为3至7。
本发明还提供了一种使用含有聚维酮碘的组合物的方法,在一个实施方案中,对受试者给药的容量是介于约10微升至约200微升之间,在另一个实施方案中,介于约20微升至约100微升之间,在另一个实施方案中,介于约50微升至约80微升之间,在另一个实施方案中,每只眼睛约给药一滴。一方面,每滴溶液介于约50微升至约80微升之间。
在一个实施方案中,给药频率的范围可以是每天1至100次范围内的任意一个数值。在另一个实施方案中,给药频率可以是每天2至24次。在另一个实施方案中,给药频率可以是每天2至4次。本领域技术人员可以筛选鉴定出精确的给药方案,组合物可局部使用,每只眼给药一滴,每天约1至24次。例如,每天使用该药液1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,48或96次。
实施例
本发明记载以下实施例供参考。提供的这些实施例的目的仅仅为了解释本发明,不应被理解为本发明仅限于这些实施例,而应理解为包括根据此处教导而得出的任意及所有变化的技术方案。
实施例1:用PVP-I防腐的人工泪液的抗菌防腐有效性试验
包含至少一种本申请所述人工泪液组分的组合物,其还包括可作为防腐剂使用的PVP-I,对本发明所述组合物——例如含有PVP-I的眼科药剂——的防腐性能的试验,例如使用美国药典(USP)<51>所述的方法,或使用本领域公知用于测定抗菌性防腐剂有效性的方法。根据此处所述方法制备浓度以重量计为约0.36%的PVP-I溶液。按照一个非限制实施例的方法,根据最终产品的需要,使用含有以重量计约0.36%的PVP-I制得含PVP-I的溶液,并将PVP-I与0.01%依地酸二钠,1.2%硫酸钠,0.25%羟乙基纤维素,0.5%泰洛沙泊,0.35%氯化钠混合,以调整重量摩尔渗透压浓度(osmolality)至300-350mOsm/kg,使用氢氧化钠和/或硫酸调整pH值至约4.0,并添加足量的纯净水至总体积为100%。
使用已选择的系列标准实验室菌株来检验该试验溶液。周期间隔为0,7,14,28天,除去样品并分析确定生存株。
实施例2:用PVP-I防腐的0.1%地塞米松混悬液的抗菌防腐性能试验
对本发明所述组合物-如含有PVP-I的眼科药剂-的防腐性能的试验,例如使用美国药典(USP)<51>方法,或使用本领域公知用于测定抗菌性防腐剂有效性的方法。根据此处所述方法制备浓度以重量计为约0.18%和约0.36%的PVP-I溶液。按照一个非限制实施例的方法,根据最终产品的需要,使用含有以重量计约0.18%或约0.36%的PVP-I制备含PVP-I的溶液,并将PVP-I与0.1%地塞米松,0.01%依地酸二钠,1.2%硫酸钠,0.25%羟乙基纤维素,0.5%泰洛沙泊,0.35%氯化钠混合,以调整重量摩尔渗透压浓度(osmolality)至300-350mOsm/kg,使用氢氧化钠和/或硫酸调整pH值至4.0,并添加足量的纯净水至总体积为100%。使用已选择的系列标准实验菌株来检验该试验溶液。周期间隔为0,7,14,28天,除去样品并分析确定生存株。
实施例3:用PVP-I防腐的溶液的抗微生物活性
按照一个非限制实例的方法,根据此处所述方法制备浓度以重量计为约0.36%的PVP-I溶液。按照一个非限制实施例的方法,根据最终产品的需要,使用以重量计为0.36%的PVP-I制备含PVP-I的溶液。并将PVP-I与0.1%地塞米松,0.01%依地酸二钠,1.2%硫酸钠,0.25%羟乙基纤维素,0.5%泰洛沙泊,0.35%氯化钠混合,以调整重量摩尔渗透压浓度(osmolality)至300-350mOsm/kg,使用氢氧化钠和/或硫酸调整pH值至4.0,并添加足量的纯净水至总体积为100%。然后测试这些溶液的体外微生物活性。可通过抗微生物-例如抑制口腔(P.gingivalis)中发现的细菌或抑制其他细菌-来检验其抗微生物活性。另一个例子是,通过一系列对数期培养的革兰氏阴性菌和革兰氏阳性菌来进行杀菌时间试验,这些菌株包括庆大霉素耐药假单胞菌属绿脓杆菌(Pseudomonas aeruoinosa),甲氧西林耐药金黄色葡萄球菌(staph aureus),大肠杆菌,沙眼衣原体(chlamydiatrachoma)和选定的病毒。使用的对照可以包括市售抗菌眼科药剂。在30秒,1,2,5,10和15分钟时抽取细菌样品,并转移至含有碘灭活剂的培养基。同样地,病毒灭杀时间试验中,在一分钟时抽取样品并转移到失活介质。将试验样品的结果与对照样品进行对比,以评估本发明组合物的抗菌活性水平。
实施例4:用PVP-I防腐的0.3%妥布霉素和0.1%地塞米松混悬液的制备
根据此处所述方法制备浓度以重量计为从约0.36%至约0.6%的用PVP-I防腐的不含BAK的眼用混悬液。按照一个非限制实例的方法,根据最终产品的需要,使用以重量计为0.36%,0.48%,或0.6%的PVP-I制备组合物,并与0.3%妥布霉素,0.1%地塞米松,0.01%依地酸二钠,1.2%硫酸钠,0.25%羟乙基纤维素,0.5%泰洛沙泊,0.35%氯化钠混合,以调整重量摩尔渗透压浓度(osmolality)至300-350mOsm/kg,使用氢氧化钠和/或硫酸调整pH值至约4.0,并添加足量的纯净水至总体积为100%。
实施例5:用PVP-I防腐的0.3%妥布霉素溶液的制备
根据此处所述方法制备浓度以重量计为从约0.36%至约0.6%的用PVP-I防腐的不含BAK的妥布霉素眼科溶液。按照一个非限制实例的方法,根据最终产品的需要,使用以重量计为0.36%,0.48%,或0.6%的PVP-I制备组合物,并与0.3%妥布霉素,硼酸,硫酸钠,氯化钠,泰洛沙泊,氢氧化钠和/或硫酸(用于调节pH值)和纯净水相混合。
实施例6:用PVP-I防腐的0.5%盐酸莫西沙星眼科溶液的制备
根据此处所述方法制备浓度以重量计为从约0.36%至约0.6%的用PVP-I防腐的不含BAK的盐酸莫西沙星眼科溶液。按照一个非限制实例的方法,根据最终产品的需要,使用以重量计为0.36%,0.48%,或0.6%的PVP-I制备组合物,并与0.5%盐酸莫西沙星,硼酸,氯化钠,和纯净水混合。在一个实施方案中,防腐的滴眼液含有盐酸和/或氢氧化钠以调节pH值。
实施例7:用PVP-I防腐的1.0%醋酸泼尼松龙混悬液的制备
根据此处所述方法制备浓度以重量计为从约0.36%至约0.6%的用PVP-I防腐的不含BAK的醋酸泼尼松龙混悬液。按照一个非限制实例的方法,根据最终产品的需要,使用以重量计为0.36%,0.48%,或0.6%的PVP-I制备组合物,并与1.0%醋酸泼尼松龙,硼酸,依地酸二钠,羟丙甲纤维素,吐温80,亚硫酸氢钠,枸橼酸钠,氯化钠和纯净水混合。
此处通过记载具体实施例描述了本发明。然而,由于所属领域技术人员容易对它们进行改变,因此根据此处所公开的内容,本发明不应被认为仅限于所述实施例。所有专利,专利申请,和引用的参考文献均全文引入本申请作为参考。
Claims (7)
1.一种眼科制剂,该制剂包含:
a.浓度选自0.01%至10%、0.1%至2.5%、0.2至1.5%、0.3%至1.0%的聚维酮碘(PVP-I),和
b.莫西沙星。
2.权利要求1所述的眼科制剂,其中所述莫西沙星以0.001~1.0wt%的浓度存在。
3.权利要求1所述的眼科制剂,其中所述PVP-I以0.5%的浓度存在。
4.权利要求2所述的眼科制剂,其中所述PVP-I的浓度是在相对于整个制剂的重量/重量基础上测量的。
5.权利要求2所述的眼科制剂,其中所述PVP-I的浓度是在相对于整个制剂的重量/体积基础上测量的。
6.根据权利要求1所述的眼科制剂,其中所述制剂进一步包含增粘剂。
7.权利要求6所述的眼科制剂,其中所述的增粘剂选自聚乙烯醇、聚乙烯吡咯烷酮、甲基纤维素、羟丙基甲基纤维素、羟乙基纤维素、羧甲基纤维素、羟丙基纤维素,和它们的任意组合。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12922208P | 2008-06-12 | 2008-06-12 | |
US61/129222 | 2008-06-12 | ||
US20185408P | 2008-12-15 | 2008-12-15 | |
US61/201854 | 2008-12-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801222637A Division CN102118973A (zh) | 2008-06-12 | 2009-06-10 | 一种眼科组合物中新的防腐剂替代物聚维酮碘 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104189911A true CN104189911A (zh) | 2014-12-10 |
Family
ID=41417019
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610391491.6A Pending CN105944105A (zh) | 2008-06-12 | 2009-06-10 | 一种眼科组合物中的防腐剂替代物聚维酮碘 |
CN2009801222637A Pending CN102118973A (zh) | 2008-06-12 | 2009-06-10 | 一种眼科组合物中新的防腐剂替代物聚维酮碘 |
CN201410353170.8A Pending CN104189911A (zh) | 2008-06-12 | 2009-06-10 | 眼科组合物中的防腐剂替代物聚维酮碘 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610391491.6A Pending CN105944105A (zh) | 2008-06-12 | 2009-06-10 | 一种眼科组合物中的防腐剂替代物聚维酮碘 |
CN2009801222637A Pending CN102118973A (zh) | 2008-06-12 | 2009-06-10 | 一种眼科组合物中新的防腐剂替代物聚维酮碘 |
Country Status (20)
Country | Link |
---|---|
US (2) | US20120027716A1 (zh) |
EP (2) | EP2291081B1 (zh) |
JP (4) | JP2011522891A (zh) |
KR (3) | KR20160045153A (zh) |
CN (3) | CN105944105A (zh) |
AU (1) | AU2009258145A1 (zh) |
BR (1) | BRPI0913417B1 (zh) |
CA (2) | CA2937997A1 (zh) |
CL (1) | CL2010001406A1 (zh) |
CO (1) | CO6341526A2 (zh) |
DK (1) | DK2291081T3 (zh) |
EC (1) | ECSP11010755A (zh) |
ES (1) | ES2810863T3 (zh) |
HK (1) | HK1202074A1 (zh) |
MX (2) | MX338674B (zh) |
NZ (3) | NZ625086A (zh) |
PE (2) | PE20141185A1 (zh) |
PL (1) | PL2291081T3 (zh) |
PT (1) | PT2291081T (zh) |
WO (1) | WO2009151619A1 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090263345A1 (en) * | 2008-01-28 | 2009-10-22 | Foresight Biotherapeutics, Inc. | Otic compositions for the treatment of infections of the internal and external ear in mammals |
PE20121498A1 (es) * | 2009-12-15 | 2012-11-30 | Foresight Biotherapeutics Inc | Composiciones oftalmicas no irritantes de povidona-yodo |
AU2015252097A1 (en) * | 2009-12-15 | 2015-11-19 | Foresight Biotherapeutics, Inc. | Non-irritating ophthalmic povidone-iodine compositions |
WO2012073856A1 (ja) * | 2010-11-29 | 2012-06-07 | 千寿製薬株式会社 | ジフルプレドナートおよびトブラマイシンを含有する水中油型エマルジョン組成物 |
BR112013018025A2 (pt) * | 2011-01-18 | 2020-10-27 | Senju Pharmaceutical Co., Ltd | composição de bromfenac líquida aquosa método para reforçar a eficácia conservante de uma solução aquosa |
BR112013028735A2 (pt) * | 2011-05-12 | 2017-12-05 | Foresight Biotherapeutics Inc | composições estáveis de iodopovidona com esteróides ou anti-inflamatórios não esteróides |
TW201808311A (zh) * | 2011-09-16 | 2018-03-16 | 遠景生物製藥股份有限公司 | 安定之普維酮-碘組成物 |
JP6161500B2 (ja) * | 2012-10-05 | 2017-07-12 | ロート製薬株式会社 | ブロムフェナク含有組成物 |
US9630909B2 (en) | 2013-06-27 | 2017-04-25 | Mylan Laboratories Ltd | Process for the preparation of nepafenac |
DE102014010694A1 (de) | 2014-07-09 | 2016-01-28 | Beuth Hochschule Für Technik Berlin | Jod enthaltende pharmazeutische Zusammensetzung mit antimikrobiellen Eigenschaften sowie Verfahren zur Herstellung |
JP6280675B1 (ja) * | 2015-01-20 | 2018-02-14 | ヴェローチェ・バイオファーマ・エルエルシー | 新規ヨードフォア組成物および使用方法 |
ITUA20162425A1 (it) * | 2016-04-08 | 2017-10-08 | Medivis S R L | Composizione oftalmica che comprende PVP-I |
CN110114119B (zh) * | 2016-10-12 | 2022-05-31 | Ps治疗有限公司 | 人工泪液、隐形眼镜和药物载体组合物及其使用方法 |
JP6320616B1 (ja) * | 2017-08-22 | 2018-05-09 | ヴェローチェ・バイオファーマ・エルエルシー | 新規眼科用組成物および使用方法 |
CA3145888A1 (en) * | 2018-07-31 | 2020-02-06 | Isilay KAVADARLI | Ophthalmic formulations and uses thereof |
JP7479744B2 (ja) | 2022-01-21 | 2024-05-09 | センジュ ユーエスエー、インコーポレイテッド | 水性液剤 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5414011A (en) * | 1987-09-11 | 1995-05-09 | Syntex (U.S.A.) Inc. | Preservative system for ophthalmic formulations |
CA1303503C (en) * | 1987-11-10 | 1992-06-16 | Marc Plamondon | Ophthalmic solution comprising iodine-polyvinylpyrrolidone complex |
JP2617139B2 (ja) * | 1988-03-09 | 1997-06-04 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼科用途の為のトブラマイシンとステロイドの組合わせ |
US5126127A (en) * | 1991-07-16 | 1992-06-30 | Euroceltique, S.A. | Stabilized PVP-I solutions |
US6328991B1 (en) * | 1992-10-21 | 2001-12-11 | John Myhling | Composition and method for prevention of sexually transmitted diseases, including aids |
MXPA05007813A (es) * | 2003-03-10 | 2005-10-18 | Xantech Pharmaceuticals Inc | Composicion con mejor desempeno antimicrobiano para higienizar superficies. |
US20050095205A1 (en) * | 2003-10-31 | 2005-05-05 | Ramesh Krishnamoorthy | Combination of loteprednol etabonate and tobramycin for topical ophthalmic use |
EP1683526B1 (en) * | 2003-11-14 | 2012-04-11 | Senju Pharmaceutical Co., Ltd. | Aqueous solution preparation containing aminoglycoside antibiotic and bromfenac |
US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
US20070297990A1 (en) * | 2006-06-27 | 2007-12-27 | Shah Mandar V | Self-preserving composition |
-
2009
- 2009-06-10 KR KR1020167009750A patent/KR20160045153A/ko not_active Application Discontinuation
- 2009-06-10 US US12/997,374 patent/US20120027716A1/en not_active Abandoned
- 2009-06-10 CN CN201610391491.6A patent/CN105944105A/zh active Pending
- 2009-06-10 PT PT97629158T patent/PT2291081T/pt unknown
- 2009-06-10 AU AU2009258145A patent/AU2009258145A1/en not_active Abandoned
- 2009-06-10 CN CN2009801222637A patent/CN102118973A/zh active Pending
- 2009-06-10 EP EP09762915.8A patent/EP2291081B1/en active Active
- 2009-06-10 PE PE2013002829A patent/PE20141185A1/es not_active Application Discontinuation
- 2009-06-10 WO PCT/US2009/003521 patent/WO2009151619A1/en active Application Filing
- 2009-06-10 DK DK09762915.8T patent/DK2291081T3/da active
- 2009-06-10 ES ES09762915T patent/ES2810863T3/es active Active
- 2009-06-10 NZ NZ625086A patent/NZ625086A/en not_active IP Right Cessation
- 2009-06-10 KR KR1020117000308A patent/KR20110018414A/ko not_active Application Discontinuation
- 2009-06-10 CA CA2937997A patent/CA2937997A1/en not_active Abandoned
- 2009-06-10 PE PE2010001131A patent/PE20110162A1/es not_active Application Discontinuation
- 2009-06-10 CA CA2727605A patent/CA2727605C/en active Active
- 2009-06-10 NZ NZ747878A patent/NZ747878A/en not_active IP Right Cessation
- 2009-06-10 PL PL09762915T patent/PL2291081T3/pl unknown
- 2009-06-10 MX MX2010013670A patent/MX338674B/es active IP Right Grant
- 2009-06-10 EP EP20177593.9A patent/EP3777536A1/en not_active Withdrawn
- 2009-06-10 CN CN201410353170.8A patent/CN104189911A/zh active Pending
- 2009-06-10 JP JP2011513502A patent/JP2011522891A/ja active Pending
- 2009-06-10 KR KR1020187002881A patent/KR20180014859A/ko not_active Application Discontinuation
- 2009-06-10 NZ NZ603346A patent/NZ603346A/en not_active IP Right Cessation
- 2009-06-10 BR BRPI0913417-4A patent/BRPI0913417B1/pt not_active IP Right Cessation
-
2010
- 2010-12-10 MX MX2020003159A patent/MX2020003159A/es unknown
- 2010-12-10 CL CL2010001406A patent/CL2010001406A1/es unknown
-
2011
- 2011-01-11 CO CO11002094A patent/CO6341526A2/es not_active Application Discontinuation
- 2011-01-12 EC EC2011010755A patent/ECSP11010755A/es unknown
-
2013
- 2013-05-16 US US13/895,815 patent/US20130251666A1/en not_active Abandoned
-
2015
- 2015-01-30 JP JP2015016925A patent/JP6527341B2/ja not_active Expired - Fee Related
- 2015-03-17 HK HK15102686.8A patent/HK1202074A1/zh unknown
-
2018
- 2018-11-30 JP JP2018225410A patent/JP2019052172A/ja active Pending
-
2020
- 2020-11-16 JP JP2020190405A patent/JP2021035984A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104189911A (zh) | 眼科组合物中的防腐剂替代物聚维酮碘 | |
CN102811610B (zh) | 无刺激性眼科聚维酮碘组合物 | |
EP2680829B1 (en) | Compositions and methods for non-surgical treatment of ptosis | |
JP7072898B2 (ja) | ポリミキシンb/トリメトプリム系の治療薬を含有する医薬組成物 | |
JP2016183198A (ja) | ボレート−ポリオール複合体を含む水性薬学的組成物 | |
TW201109325A (en) | Aqueous composition for eye drops | |
CN101977588A (zh) | 具有所需生物利用度的药物组合物 | |
CA3107590A1 (en) | Spinosyn formulations for treatment of demodex-induced ocular and facial conditions | |
JP6941157B2 (ja) | 眼科用組成物 | |
JP7358526B2 (ja) | 向上した眼の快適性を提供する組成物 | |
US20220071924A1 (en) | Treatment of ocular diseases with ophthalmic tapinarof compositions | |
CN101564397A (zh) | 一种含有二氟泼尼酯和妥布霉素眼用或者耳鼻用组合物及其用途 | |
CN102497854A (zh) | 含有作为防腐剂的丙酸衍生物的眼用液体药物组合物 | |
WO2005072727A1 (ja) | 点眼剤組成物 | |
CN110354074A (zh) | 一种缓释型盐酸莫西沙星眼用制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1202074 Country of ref document: HK |
|
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141210 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1202074 Country of ref document: HK |